U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C18H13N7
Molecular Weight 327.3427
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of FR-180204

SMILES

NC1=NNC2=NN=C(C=C12)C3=C4C=CC=CN4N=C3C5=CC=CC=C5

InChI

InChIKey=XVECMUKVOMUNLE-UHFFFAOYSA-N
InChI=1S/C18H13N7/c19-17-12-10-13(20-22-18(12)23-21-17)15-14-8-4-5-9-25(14)24-16(15)11-6-2-1-3-7-11/h1-10H,(H3,19,21,22,23)

HIDE SMILES / InChI

Molecular Formula C18H13N7
Molecular Weight 327.3427
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/17123065 | https://www.ncbi.nlm.nih.gov/pubmed/24704674

FR 180204 is a novel and selective inhibitor of extracellular signal-regulated kinase (ERK), which may be a potential new therapy for rheumatoid arthritis. FR 180204 inhibited ERK1 and ERK2 with an IC50 value of 0.51 uM (Ki = 0.31 uM) and 0.33 uM (Ki = 0.14 uM), respectively. FR 180204 may be useful as a therapeutic agent for the treatment of cancer, immune diseases, ischemic brain injury, and obesity. In a mouse model of dengue virus (DENV) infection, FR 180204 limits hepatocyte apoptosis, reduces DENV-induced liver injury, and improves Clinical parameters.

Originator

Curator's Comment: Ohori M et al., Lead Discovery Research Laboratories, Astellas Pharma Inc., Japan

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Patents

Sample Use Guides

Mice: In collagen-induced arthritis mice, FR 180204 (100 mg/kg, i.p., b.i.d.) significantly decreases the severity of symptoms and body weight loss.
Route of Administration: Intraperitoneal
FR 180204 dose-dependently inhibited AP-1 transactivation, with an IC50 of 3.1 uM.
Substance Class Chemical
Created
by admin
on Sat Dec 16 09:16:56 UTC 2023
Edited
by admin
on Sat Dec 16 09:16:56 UTC 2023
Record UNII
4C7X7GV82C
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
FR-180204
Code English
5-(2-PHENYLPYRAZOLO(1,5-A)PYRIDIN-3-YL)-2H-PYRAZOLO(3,4-C)PYRIDAZIN-3-AMINE
Systematic Name English
1H-PYRAZOLO(3,4-C)PYRIDAZIN-3-AMINE, 5-(2-PHENYLPYRAZOLO(1,5-A)PYRIDIN-3-YL)-
Systematic Name English
FR180204
Code English
ERK INHIBITOR II
Common Name English
Code System Code Type Description
FDA UNII
4C7X7GV82C
Created by admin on Sat Dec 16 09:16:56 UTC 2023 , Edited by admin on Sat Dec 16 09:16:56 UTC 2023
PRIMARY
EPA CompTox
DTXSID30693489
Created by admin on Sat Dec 16 09:16:56 UTC 2023 , Edited by admin on Sat Dec 16 09:16:56 UTC 2023
PRIMARY
PUBCHEM
11493598
Created by admin on Sat Dec 16 09:16:56 UTC 2023 , Edited by admin on Sat Dec 16 09:16:56 UTC 2023
PRIMARY
CAS
865362-74-9
Created by admin on Sat Dec 16 09:16:56 UTC 2023 , Edited by admin on Sat Dec 16 09:16:56 UTC 2023
PRIMARY
Related Record Type Details
ACTIVE MOIETY